Krka, d. d. (KRK.WA)
PLN 744.0
(1.64%)
PLN 744.0
(1.64%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 472.19 Million EUR | -12.75% |
| 2022 | 542.01 Million EUR | 11.11% |
| 2021 | 471.74 Million EUR | 8.42% |
| 2020 | 450.99 Million EUR | 8.52% |
| 2019 | 396.08 Million EUR | 31.38% |
| 2018 | 341.12 Million EUR | 19.28% |
| 2017 | 305.4 Million EUR | -3.36% |
| 2016 | 227.44 Million EUR | -0.52% |
| 2015 | 286.21 Million EUR | -0.55% |
| 2014 | 373.98 Million EUR | -8.07% |
| 2013 | 321.22 Million EUR | 3.63% |
| 2012 | 282.05 Million EUR | -5.47% |
| 2011 | 301.19 Million EUR | 2.73% |
| 2010 | 293.19 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 165.74 Million EUR | 6.28% |
| 2024 Q1 | 137.51 Million EUR | 33.45% |
| 2023 Q3 | 100.06 Million EUR | -21.9% |
| 2023 Q4 | 103.04 Million EUR | 2.98% |
| 2023 FY | - EUR | -12.75% |
| 2023 Q1 | 134.54 Million EUR | 36.7% |
| 2023 Q2 | 128.13 Million EUR | -4.77% |
| 2022 Q1 | 123.45 Million EUR | 13.46% |
| 2022 Q2 | 206.98 Million EUR | 67.66% |
| 2022 Q3 | 102.31 Million EUR | -50.57% |
| 2022 Q4 | 98.42 Million EUR | -3.8% |
| 2022 FY | - EUR | 11.11% |
| 2021 Q2 | 137.07 Million EUR | 7.22% |
| 2021 FY | - EUR | 8.42% |
| 2021 Q3 | 104.34 Million EUR | -23.88% |
| 2021 Q4 | 108.81 Million EUR | 4.28% |
| 2021 Q1 | 127.84 Million EUR | 11.51% |
| 2020 Q4 | 114.65 Million EUR | 34.54% |
| 2020 Q2 | 123.72 Million EUR | 5.41% |
| 2020 Q1 | 117.36 Million EUR | 5.54% |
| 2020 FY | - EUR | 8.52% |
| 2020 Q3 | 85.21 Million EUR | -31.12% |
| 2019 Q3 | 68 Million EUR | -39.31% |
| 2019 Q4 | 111.2 Million EUR | 63.52% |
| 2019 Q2 | 112.05 Million EUR | -2.62% |
| 2019 Q1 | 115.07 Million EUR | 32.77% |
| 2019 FY | - EUR | 31.38% |
| 2018 Q3 | 48.83 Million EUR | -44.07% |
| 2018 FY | - EUR | 19.28% |
| 2018 Q2 | 87.32 Million EUR | 1.0% |
| 2018 Q1 | 86.46 Million EUR | 90.03% |
| 2018 Q4 | 86.67 Million EUR | 77.46% |
| 2017 Q3 | 46.67 Million EUR | -41.11% |
| 2017 Q2 | 79.26 Million EUR | -9.81% |
| 2017 Q1 | 87.87 Million EUR | 36.12% |
| 2017 Q4 | 45.5 Million EUR | -2.52% |
| 2017 FY | - EUR | -3.36% |
| 2016 Q2 | 80.86 Million EUR | -7.52% |
| 2016 FY | - EUR | -0.52% |
| 2016 Q1 | 87.43 Million EUR | 101.65% |
| 2016 Q4 | 64.55 Million EUR | 82.01% |
| 2016 Q3 | 35.47 Million EUR | -56.14% |
| 2015 Q1 | 90.66 Million EUR | 71.54% |
| 2015 Q2 | 90.92 Million EUR | 0.29% |
| 2015 FY | - EUR | -0.55% |
| 2015 Q4 | 43.36 Million EUR | -3.17% |
| 2015 Q3 | 44.78 Million EUR | -50.75% |
| 2014 FY | - EUR | -8.07% |
| 2014 Q2 | 99.08 Million EUR | 36.44% |
| 2014 Q4 | 52.85 Million EUR | 13.24% |
| 2014 Q3 | 46.67 Million EUR | -52.89% |
| 2014 Q1 | 72.62 Million EUR | -7.29% |
| 2013 Q3 | 52.98 Million EUR | -33.87% |
| 2013 Q4 | 78.33 Million EUR | 47.83% |
| 2013 FY | - EUR | 3.63% |
| 2013 Q1 | 83.59 Million EUR | 16.72% |
| 2013 Q2 | 80.12 Million EUR | -4.15% |
| 2012 Q4 | 71.62 Million EUR | 26.43% |
| 2012 Q2 | 71.39 Million EUR | -18.17% |
| 2012 Q1 | 87.24 Million EUR | 28.06% |
| 2012 FY | - EUR | -5.47% |
| 2012 Q3 | 56.65 Million EUR | -20.65% |
| 2011 FY | - EUR | 2.73% |
| 2011 Q4 | 68.13 Million EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Celon Pharma S.A. | 32.71 Million PLN | -1343.4% |